H. Shaw Warren, M.D. is a physician and pediatrician at Massachusetts General Hospital in Boston and an Associate Professor at Harvard Medical School. He is also a member of the Medical and Scientific Staff of the Shriners Burns Institute and an
associate faculty member of the Wyss Institute in Boston. Dr. Warren’s research interest has been in the area of bacterial infections, host response and inflammation. His laboratory has been continuously funded by a variety of governmental agencies for 30 years, and he has published over 100 articles and chapters, many in high impact journals. His work has focused on both basic science and as well as on analysis of clinical studies of inflammation induced by infection. In 2013 he reported data suggesting that the acute inflammatory response of mice differs markedly from that of humans, a finding that has substantial implications for drug development. He is director of SPIRIT (Species Inspired Research for Innovative Treatments), a multi-institutional program whose overarching goal is to discover better approaches for drug development based upon differences in the ways that species respond to pro-inflammatory challenge. Most recently Dr. Warren has started to explore novel approaches to kill microorganisms in tissues. Dr. Warren was a co-founder of Critical Therapeutics, Inc (CRTX) in 1988, and was a member of the board of directors from 2000 to 2004, remaining on the board after it went public in 2003. He co-founded Setpoint Medical, Inc in 2006, and Cidara, Inc (CDTX) in 2012.